These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 31955626)

  • 41. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
    Habu M; Okada Y; Kurozumi A; Tanaka Y
    J UOEH; 2020; 42(4):359-364. PubMed ID: 33268615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
    Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
    Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
    Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
    Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
    Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
    Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
    [No Abstract]   [Full Text] [Related]  

  • 46. Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
    Mori K; Tsuchiya K; Nakamura S; Miyachi Y; Shiba K; Ogawa Y; Kitamura K
    Cardiovasc Diabetol; 2019 Jun; 18(1):83. PubMed ID: 31234839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
    Elgebaly A; Abdelazeim N; Abdelazeim B; El Ashal G; Mattar O; Namous L; Nasreldin N
    Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):56-72. PubMed ID: 29913526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
    Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
    PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
    Komatsu S; Nomiyama T; Numata T; Kawanami T; Hamaguchi Y; Iwaya C; Horikawa T; Fujimura-Tanaka Y; Hamanoue N; Motonaga R; Tanabe M; Inoue R; Yanase T; Kawanami D
    Endocr J; 2020 Jan; 67(1):99-106. PubMed ID: 31776304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
    Yabiku K; Nakamoto K; Tsubakimoto M
    J Diabetes Res; 2020; 2020():1682904. PubMed ID: 33457424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
    Chen W; Li P; Wang G; Chen Y; Wang B; Chen M
    Postgrad Med; 2019 Nov; 131(8):578-588. PubMed ID: 31414934
    [No Abstract]   [Full Text] [Related]  

  • 52. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
    Takahashi H; Kessoku T; Kawanaka M; Nonaka M; Hyogo H; Fujii H; Nakajima T; Imajo K; Tanaka K; Kubotsu Y; Isoda H; Oeda S; Kurai O; Yoneda M; Ono M; Kitajima Y; Tajiri R; Takamori A; Kawaguchi A; Aishima S; Kage M; Nakajima A; Eguchi Y; Anzai K
    Hepatol Commun; 2022 Jan; 6(1):120-132. PubMed ID: 34558835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.
    Katsuno K; Fujimori Y; Ishikawa-Takemura Y; Isaji M
    Eur J Pharmacol; 2009 Sep; 618(1-3):98-104. PubMed ID: 19615995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
    Koshizaka M; Ishikawa K; Ishibashi R; Maezawa Y; Sakamoto K; Uchida D; Nakamura S; Yamaga M; Yokoh H; Kobayashi A; Onishi S; Kobayashi K; Ogino J; Hashimoto N; Tokuyama H; Shimada F; Ohara E; Ishikawa T; Shoji M; Ide S; Ide K; Baba Y; Hattori A; Kitamoto T; Horikoshi T; Shimofusa R; Takahashi S; Nagashima K; Sato Y; Takemoto M; Newby LK; Yokote K;
    J Diabetes Investig; 2021 Feb; 12(2):200-206. PubMed ID: 32623839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
    Tanaka S; Sugiura Y; Saito H; Sugahara M; Higashijima Y; Yamaguchi J; Inagi R; Suematsu M; Nangaku M; Tanaka T
    Kidney Int; 2018 Nov; 94(5):912-925. PubMed ID: 30021702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
    Tanaka M; Yamakage H; Inoue T; Odori S; Kusakabe T; Shimatsu A; Satoh-Asahara N
    Intern Med; 2020; 59(5):601-609. PubMed ID: 32115517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.
    Lee JY; Lee M; Lee JY; Bae J; Shin E; Lee YH; Lee BW; Kang ES; Cha BS
    Diabetes Metab J; 2021 Nov; 45(6):921-932. PubMed ID: 33611885
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metformin supports the antidiabetic effect of a sodium glucose cotransporter 2 inhibitor by suppressing endogenous glucose production in diabetic mice.
    Neschen S; Scheerer M; Seelig A; Huypens P; Schultheiss J; Wu M; Wurst W; Rathkolb B; Suhre K; Wolf E; Beckers J; Hrabé de Angelis M
    Diabetes; 2015 Jan; 64(1):284-90. PubMed ID: 25071027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.